- ANGLE plc unveiled a new CTC-based assay for monitoring Androgen Receptor (AR) expression in prostate cancer at EACR 2025.
- Clinical tests showed 50% of mCRPC patients were CTC-positive, with all having AR-positive CTCs.
- The AR inhibitor market is projected to reach $9.8 billion by 2032.
ANGLE plc (ANPCY, Financial) presented groundbreaking data at the European Association for Cancer Research (EACR) Congress 2025, demonstrating a novel circulating tumor cell (CTC)-based assay for Androgen Receptor (AR) expression profiling in prostate cancer. Using the Parsortix system combined with an AR immunofluorescence assay, ANGLE's new approach offers high sensitivity in monitoring AR expression levels.
In initial testing with blood samples spiked with prostate cancer cells, the assay effectively reduced AR expression from over 80% AR-positive cells to under 20% as AR-drug concentrations increased. This indicates a significant potential for real-time treatment response monitoring. Clinical validation in 20 patients with metastatic castration-resistant prostate cancer (mCRPC) revealed that 50% were CTC-positive, and each had AR-positive CTCs.
The new assay addresses an essential demand in the growing AR inhibitor market, projected to reach $9.8 billion by 2032. With over 130 ongoing clinical studies, the need for precise assays capable of monitoring AR activity is increasingly critical. ANGLE's assay is now commercially available to pharmaceutical customers, helping them with longitudinal biomarker assessments in AR-targeted clinical trials.
